Skip to main content
SpringerLink
Log in

Alectinib/ceritinib/crizotinib

Gastrointestinal disorders and liver disorders: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Shen G, et al. Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report. OncoTargets and Therapy 14: 5471-5475, 23 Dec 2021. Available from: URL: https://doi.org/10.2147/OTT.S340984

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alectinib/ceritinib/crizotinib. Reactions Weekly 1938, 45 (2023). https://doi.org/10.1007/s40278-023-30186-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-30186-3

Search

Navigation